Sunday, 12 April 2020

Medical Drones Market 2020 Business Trends, Regional Study, Size, Share, Industry Profit Growth and Global Segments by Forecast to 2025

Market Highlights
According to MRFR analysis, Medical Drones Market growth is expected to register a CAGR of 24.4% during the forecast period of 2019 to 2025 and was valued at USD 85.84 Million in 2018.
Medical drones help to carry medical supplies that consist of medications, vaccines, and medical aids, among others. These drones are used in isolated or inaccessible areas for the rapid and secure distribution of medical supplies and also to war-torn areas from medical facilities.
The growth of the global medical drones market is attributed to factors such as the rising number of government initiatives, applications of medical drones, research & development activities, and public acceptance. However, strict laws associated with the approval of medical drones are likely to hamper the growth of the market during the forecast period.
The key players in the medical drones market are aggressively involved in R&D, geographic expansions, product launches, and strategic collaborations to strengthen their market positions.
Regional Analysis
The market has been divided by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is anticipated to hold the largest market share throughout the forecast period owing to the aggressive R&D activity by public and private organizations in the US, raising awareness, and strategic alliances between key players. For instance, between July to Sep 2019, Zipline a US-based drone company entered the partnerships with the DoD and Naval Medical Research Center to provide drones throughout four multinational military forces exercises in Australia. The medical drones market in the Americas has further been divided into North America and Latin America, with the North American market further divided into the US and Canada.
The European medical drones market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The medical drones market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the presence of a large patient pool and expansion of healthcare facilities, the market in Asia-Pacific is expected to be the fastest-growing during the forecast period. The Medical Drones market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The Global Medical Drones Market has been segmented based on applications and end-user.
The market, based on application, has been segmented into blood transfer, pharmaceutical/drug transfer, vaccine transfer, and others. The blood transfer segment is expected to witness healthy growth during the forecast period owing to the rising number of deaths due to severe bleeding. For instance, each year around 2 million people die from blood loss or hemorrhaging across the globe.
The global medical drones market based on end-user has been segregated into emergency medical services, blood banks, and others.
Key Players
Some of the Key Players in the Global Medical Drones Market are DJI (China), DHL (Germany), Embention (Spain), Flirtey (US), Matternet (US), Vayu (US), Zipline (US), EHang (China), TUDelft (The Netherlands), and others.
Posted by at No comments:

Thalassemia Treatment Market to Perceive Phenomenal Growth by 2025; Asserts MRFR Unleashing the forecast for 2020 -2025 up to 2025

According to MRFR analysis, Thalassemia Treatment Market is expected to register a CAGR of 10.4% during the forecast period of 2019 to 2025 and was valued at USD 1890.4 Million in 2018.
Thalassemia is an inherited blood disorder that is characterized by inadequate hemoglobin and fewer red blood cells in the body than normal. Hemoglobin is the substance in red blood cells that allows them to carry oxygen. The inadequate hemoglobin and fewer red blood cells of thalassemia may cause anemia.
The growth of the Global Thalassemia Treatment Market is driven by various factors such as rising incidence of thalassemia, increasing pipeline drugs in thalassemia, rise in awareness regarding available treatment options for the treatment of thalassemia, growing public awareness related to preventive care and rise in demand for improved curative gene therapy. However, stringent regulatory policies and high treatment costs are expected to curb the growth of the global thalassemia treatment market.
The global thalassemia treatment market growth is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of thalassemia and rising per capita healthcare expenditure. The thalassemia treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European thalassemia treatment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The thalassemia treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Increasing government initiatives to promote the thalassemia treatment technique is expected to boost the growth of the thalassemia treatment market in Asia-Pacific and is expected to be the fastest-growing. The thalassemia treatment market in the Middle East & Africa has been divided into the Middle East and Africa.
Thalassemia Treatment Market Segmentation
The Global Thalassemia Treatment Market has been segmented based on type, treatment, and end-user.
The market, based on type, has been divided into alpha-thalassemia and beta-thalassemia. The alpha-thalassemia segment is likely to be the fastest during the forecast period as there is an increased incidence of alpha-globin disorders in the US and other Western nations.
The global thalassemia treatment market has been segmented based on treatment, into blood transfusions, iron chelation therapy, folic acid supplements, gene therapy, and bone marrow transplants. The blood transfusions segment is expected to be the fastest market as low risks are involved due to careful blood screening. For instance, about 56,000 population have major thalassemia, and there are at least 30,000 people that need regular blood transfusions to survive and 5,500 die perinatally due to alpha-thalassemia major. As a result, increasing the need for blood transfusions would boost the growth of the thalassemia treatment market.
The end-user segment of the market includes hospitals and clinics, diagnostic laboratories, and others. The hospitals and clinics segment is expected to hold the largest share of the market due to the increase in the number of hospital admissions for the treatment of thalassemia across the globe.
Key Players
Some of the Key Players in the Global Thalassemia Treatment Market are Novartis AG (Switzerland), Kiadis Pharma (Netherlands), Sangamo Therapeutics (US), Gamida Cell (Israel), Acceleron Pharma, Inc. (US), CELGENE CORPORATION (US), and Bluebird Bio, Inc. (US).
Posted by at No comments:
Labels:

Cardiac Biomarkers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2020 – 2025

Market Highlights
According to MRFR analysis, Cardiac Biomarkers Market Growth is expected to register a CAGR of 16.36% during the forecast period of 2019 to 2025 and accounted for USD 1446.11 Million in 2018.
Tests for cardiac biomarkers are used to diagnose acute coronary syndrome (ACS) and cardiac ischemia, conditions associated with insufficient blood flow to the heart. These biomarkers are also helpful in determining a person's risk of having these conditions or to help monitor and manage someone with ACS and cardiac ischemia.
The increasing prevalence of cardiovascular diseases is expected to drive the growth of the global cardiac biomarkers market. Out of the 17 million premature deaths due to noncommunicable diseases in 2015, 82% were in low- and middle-income countries, and 37% were caused by cardiovascular diseases.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are expected to be the largest market owing to the high spending by the pharmaceutical industry. The cardiac biomarkers market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European cardiac biomarkers market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cardiac biomarkers market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the rising affordability for advanced cardiac treatments and increasing disposable incomes, the market in Asia-Pacific is expected to be the fastest-growing. The cardiac biomarkers market in the Middle East & Africa has been divided into the Middle East and Africa.
Cardiac Biomarkers Market Segmentation
The Global Cardiac Biomarkers Market has been segmented based on Type, Location of Testing, and Application.
The market, based on type, has been divided into myocardial muscle creatine kinase (CK-MB), troponins (T and I), myoglobin, brain natriuretic peptide (BNP) or NT-proBNP and ischemia modified albumin (IMA). Troponins (T and I) is the maximum revenue generating segment due to its high cardiac specificity. Among patients with acute coronary syndromes, troponins level has been reported to provide prognostic information useful for the early identification of patients with an elevated risk of unstable angina progressing to AMI and death.
The global cardiac biomarkers market has been segmented, on the basis of the location of testing, into point of care testing and laboratory testing. The point of care testing segment is expected to witness the fastest growth due to its increasing popularity in cardiovascular disease diagnostics.
The market, based on application, has been divided into acute coronary syndrome, myocardial infarction, congestive heart failure, atherosclerosis, and others. The acute coronary syndrome held the largest market share in 2018. It is a medical emergency that requires prompt diagnosis and care.
Key Players
Some of the Key Players in the Global Cardiac Biomarkers Market are Abbott Laboratories (US), ACS Biomarker (The Netherlands), BD (Becton, Dickinson and Company) (US), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson and Johnson (US), Quidel Corporation (US), Randox Laboratories Limited (UK), Siemens AG (Germany), Thermo Fisher Scientific, Inc. (US), Trivitron Healthcare Pvt. Ltd. (India), and Novartis (Switzerland).
Posted by at No comments:

STD Testing Devices Market Profound Impact on the Market by Growing Healthcare Sector during the Forecast Period 2020-2025

Market Highlights
According to MRFR analysis, STD Testing Devices Market is expected to register a CAGR of 9.3% during the forecast period of 2019 to 2025 and accounted for USD 70.29 Billion in 2018.
The global STD testing devices market growth is driven by various factors such as an increase in the prevalence of sexually transmitted diseases, increasing prevalence of lifestyle diseases, and increasing mergers & acquisitions by prominent players in the market. However, lack of knowledge about the symptoms is projected to hamper the growth of the global STD testing devices market.
The Global STD Testing Devices Market is currently dominated by several market players. Additionally, growing initiatives to create awareness is driving the growth of the market. For instance, Inovio Pharmaceuticals, Inc. in 2018, signed an agreement with ApolloBio Corp. for the exclusive rights for the development, manufacturing, and commercialization of VGX – 3100, Inovio’s DNA immunotherapy product. This product is used for pre-cancer indication.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the rising per capita healthcare expenditure. The STD testing devices market in the Americas has further been branched into North America and Latin America, with the North American market is divided into the US and Canada. The European STD testing devices market has been categorized into Western Europe and Eastern Europe. The Western European market has further been classified into Germany, France, UK, Italy, Spain, and the rest of Western Europe. The STD testing devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing prevalence of sexually transmitted diseases and increasing patient pool, the market in Asia-Pacific is expected to be the fastest-growing. The STD testing devices market in the Middle East & Africa has been bifurcated into the Middle East and Africa.
Segmentation
The Global STD Testing Devices Market has been segmented based on type and end-user.
The market, based on type, has been divided into laboratory devices and point of care (POC) devices. The laboratory devices segment is expected to be the largest. The laboratory devices are further segmented into thermal cyclers, cellulose-based devices, flow cytometers, enzyme-linked immunosorbent assay (ELISA) and others. The point of care devices is segmented into phone chips, rapid diagnostic kits, and others.
In terms of end-user, the global STD testing devices market has been segmented into hospitals and clinics diagnostic laboratories and research laboratories and institutes. Hospitals and clinics take up the largest share. The hospital's segment is expected to hold the largest share of the market, as these are the primary locations where patients receive treatment.
Key Players
Some of the Key Players in the Global STD Testing Devices Market are Abbott (US), Meridian Bioscience (US), Thermo Fisher Scientific (US), MedMira Inc. (Canada), F. Hoffmann-La Roche AG (Switzerland), Bio-Rad Laboratories, Inc. (US), Diasorin S.p.A (Italy), Becton Dickinson and Company (US), Hologic, Inc. (US), Cepheid (Danaher Corporation) (US), bioMeriuex (France), Qaigen Inc. (US), OraSure Technologies (US), GenePOC Inc. (Canada).
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/std-testing-devices-market-8582


Posted by at No comments:

Invisible Orthodontics Market - Positive Long-Term Growth Outlook 2025

Market Highlights
According to MRFRs's Invisible Orthodontics Markeat analysis, industry is expected to register a CAGR of 13.99% from 2019 to 2025 and held a value of USD 2598.8 Million in 2018.
Invisible orthodontic products include clear and removable braces, which are highly preferred by dental professionals for the correction of various dental disorders, such as malocclusion and crossbites, owing to their numerous benefits. These instruments are often used to correct crooked teeth, overbites, malocclusions, and other oral flaws. The growth of the global invisible orthodontics market is boosted by factors such as rising number of strategic initiatives by key players such as mergers, joint ventures, acquisitions, partnerships, coupled with the increasing number of prescriptions across the globe. Furthermore, many non-profit organizations in various countries are working towards creating awareness in the usage of orthodontics. For instance, the British Lingual Orthodontic Society (BLOS), is a membership organization focused on raising awareness about the use of lingual braces.
However, the inconvenience associated with the use of invisible orthodontic braces is a major factor hampering preference for invisible orthodontic products and is likely to restrain the market growth to a certain extent in the coming years.
Market players such as Align Technology, Inc., Dentsply Sirona, Institut Straumann AG, and 3M, currently dominate the global invisible orthodontics market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in April 2018, Align Technology, Inc. (US) commercially launched the Vivera Retainers with Precision Bite Ramps. Similarly, in April 2017, Dentsply Sirona (US) announced the expansion of treatment indications of its clear aligner. Minor Tooth Movement (MTM). This clear aligner combines proven orthodontic techniques with advanced digital modeling to provide dental professionals with a streamlined solution for treating minor anterior misalignments.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas held maximum share in the base year 2018, owing to the high incidence rates of dental-related disorders in countries such as the US. The invisible orthodontics market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European invisible orthodontics market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The invisible orthodontics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The invisible orthodontics market in this region is anticipated to be the fastest-growing during the assessment period due to the increasing awareness about the advantages of invisible orthodontic products. The invisible orthodontics market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The Global Invisible Orthodontics Market has been segmented based on product type, age group, application, and end-user.
The market, based on product type, has been divided into clear aligners, braces, and clear retainers. The clear aligners segment is held a major share in 2018 owing to the rising number of patients opting for clear aligners in the developing as well as developed countries. The braces segment was the fastest-growing segment in 2018 due to the increasing awareness created about ceramic and lingual braces by key players in the market. The market, based on clear aligners, has further segmented into hard, medium, and soft. The market, based on braces, has been further bifurcated into ceramic braces, and lingual braces.
The Global Invisible Orthodontics Market has been segmented, based on the age group, into below 15, 16 to 35, and above 35. In 2018, segment 16 to 35 held the majority share of the market owing to the increasing number of people in the age group preferring corrective dental procedures. The below 15 years segment is anticipated to be the fastest-growing during the forecast period due to the increased number of new product launches and approvals of braces and clear aligners for adolescents.
The global invisible orthodontics market, based on application, has been segmented into excessive spacing, crowding, malocclusion, abnormal eruptions, and others. The excessive spacing segment held the maximum share in 2018 owing to the rise in the number of cases, pushing the key companies in the market to invest more in research and development for the manufacturing of innovative products. The malocclusion segment is expected to be the fastest-growing during the assessment period due to the increasing number of open bite and crossbite cases in developing countries. The market, based on malocclusion, has been further segmented into open bite, deep bite, and crossbite.
Key Players
Some of the Key Players in the Global Invisible Orthodontics Market are 3M (US), Align Technology, Inc. (US), Clarus Company (US), ClearPath Healthcare Services (US), Danaher Corporation (US), Dentsply Sirona (US), DynaFlex (US), Henry Schein, Inc. (US), Institut Straumann AG (Switzerland), and Ormco (US).
Posted by at No comments:

Saturday, 11 April 2020

Global Robot-Assisted Surgical Systems Market 2020 – Investment Strategy, Outlook and Key Development till 2023

Market Insights:
The increasing need for automation in the healthcare industry and the shifting trend towards advanced robotic surgeries is anticipated to fuel the growth of the market. The high initial costs and adverse reports stand is expected to hamper the growth of the market.
Robot-assisted surgical systems industry will witness a widespread adoption since the introduction of the da Vinci surgical system by Intuitive Surgical Inc. After the system got FDA approval in 2000, da Vinci surgical system became the most widely-used surgical robot in the United States and Europe helping many cases to witness reduced length of hospital stays and lower rates of infection.
The Global Robot-Assisted Surgical Systems Market is projected to grow significantly over the forecast period. It is estimated that the global robot-assisted surgical systems market is expected to register a CAGR of ~10% during the forecast period of 2018–2023.
The global robot-assisted surgical systems market is conquered by several players. The key players are involved in new product launches, as well as strategic collaborations to brace their position in the market. For instance, in May 2015, Medtech expanded its presence in Asia with the sales of three ROSA Surgical Robots during April. This initiative is anticipated to open new avenues for the firm to cater to the untapped markets in this region.
Key Players
  • Stryker Corporation (MAKO Surgical Corp.),
  • Renishaw Plc,
  • Varian,
  • Accuray,
  • Intuitive Surgical Inc,
  • Health robotics S.R.L,
  • Smith & Nephew Plc. (Blue Belt Technologies, Inc.),
  • Auris Surgical Robotics, Inc. (Hansen Medical Inc.),
  • KUKA AG,
  • Mazor Robotics,
  • Medtronic plc,
  • THINK Surgical Inc.,
  • Zimmer Biomet Holdings Inc.,
  • Transenterix,
  • Verb Surgical,
  • Titan Medical,
  • Microbot Medical,
  • Medrobotics
Segmentation
The Global Robot-Assisted Surgical Systems Market is segmented on the basis of product, application, and end user.
Surgical robots are divided into orthopedic surgical robots, robotic neurosurgical systems, and laparoscopy robotic systems. Orthopedic Surgical Robots is divided into an iBlock surgical system, Robodoc surgical system, Navio PFS surgical system, MAKO RIO surgical system, and Stanmore Sculptor surgical system. Neurosurgical Robotic Systems is divided into Pathfinder surgical system, NeuroMate surgical system, and Renaissance surgical system. Laparoscopy Robotic Systems is divided into FreeHand endoscope holder system, Da Vinci robotic surgery system, Telelap ALF-X surgical system, and Steerable Robotic Catheters.
The robot-assisted surgical systems market by product is categorized into surgical robots, rehabilitation robots, non-invasive radiosurgery robots, hospital and pharmacy robots, and emergency response robotic systems.
Rehabilitation robots are categorized into assistive robots, prosthetics, orthotics, therapeutic robots, and robotic exoskeleton systems. Hospital and pharmacy robots are categorized into telemedicine robots, IV robots, pharmacy robots, and cart transportation robots.
Based on application, the robot-assisted surgical systems market is segmented into neurology, orthopedics robotic systems, laparoscopy, and special education.
On the basis of end user, the market is segmented into healthcare providers, healthcare payers, and others.
On the basis of region, the global robot-assisted surgical systems market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The robot-assisted surgical systems market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
It is projected that the Americas dominated the global robot-assisted surgical systems market owing to the growth of the market in the North American region. This is largely attributed to factors such as well-established healthcare infrastructure and the increase in adoption of robotic surgical systems across various healthcare settings will support market growth in this region. Europe is expected to hold the second largest share in the robot-assisted surgical systems market owing to the introduction of advanced robot-assisted laparoscopic procedures and quality of treatment of existing and new medical indications.
Asia-Pacific was projected to be the fastest growing region for the global robot-assisted surgical systems market. With the growth of the overall robotics market in the region headed by technology giants like Japan and China, the availability of medical robots has also increased. In 2017, a robot performed the world’s first automated dental implant in China. The Middle East and Africa holds the least share in the global robot-assisted surgical systems market due to the presence of economically diverse countries, and fewer initiatives taken by the government.
Posted by at No comments:

Live Cell Encapsulation Market Global Analysis, Size, Share, Trends, And Forecast 2020 to 2023

Market Scenario:
The global live cell encapsulation market is currently dominated by many market players. The key players in the market are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in August 2018, Balchem Italia S.r.l., a wholly owned subsidiary of Balchem Corporation, acquired Bioscreen Technologies, S.r.l., a privately held manufacturer of encapsulated and fermented feed nutrition ingredients. With this, the company aims to expand its position in the market.
The Global Live Cell Encapsulation Market size is expected to grow significantly over the forecast period. It is estimated that the global live cell encapsulation market is expected to register a CAGR ~ 3.22% during the forecast period of 2018 to 2023, with an estimated market value of USD 249.87 million in 2017.
Numerous factors such as a high level of research activities in live cell encapsulation technologies and the rising awareness programs in various countries are anticipated to fuel the growth of the market. Moreover, the increasing investments by various public and private organizations have created a lucrative option for many companies to invest in providing new encapsulation techniques, leading to the overall growth of the market. Furthermore, the inclination towards novel drug delivery systems for disease management fuels the growth of the market during the forecast period.
However, the lack of skilled technicians, and ethical and legal issues, and unaffordability of various small-scale companies to enter the market due to high product manufacturing costs are expected to curb the growth of live cell encapsulation market. Moreover, the availability of high-quality raw material is also restraining the growth of the market.

The Global Live Cell Encapsulation Market is driven by factors such as rising demand for clinical efficacy of cell encapsulation technologies and growing awareness related to the clinical role of encapsulated cells to treat different chronic diseases. Additionally, encapsulation provides the durability and stability of the nutrient during handling and storage. Thus, such benefits of this technique are luring the competitors to enter the market.
Key Players
Balchem Corporation, Evonik Industries, Merck KGaA, BÜCHI Labortechnik AG, Lycored, Blacktrace Holdings Ltd., Living Cell Technologies, Reed Pacific Pty Limited, MiKroCaps, Biotime, Inc., Neurotech Holdings, LLC, Sernova Corporation, Encapsys, LLC, Sigilon Therapeutics, Inc., and Viacyte, Inc. are some of the key players in the global live cell encapsulation market.
Segmentation
The Global Live Cell Encapsulation Market has been segmented into manufacturing technique, polymer type, and application. The market, based on manufacturing technique, has been segmented into simple dripping, electrostatic dripping, coaxial airflow, rotating disk atomization, and others. The market, by polymer type, has been further segmented into alginate, HEMA-MMA, Chitosan, silica, cellulose sulfate, PAN-PVC, and others. The market, by application, has been segmented into drug delivery, regenerative medicine, cell transplantation, and others. The drug delivery segment is expected to hold a major share owing to the increasing use of live cell encapsulation techniques in drug delivery systems. The segment of regenerative medicine is expected to be the fastest growing segment due to the rising trend and benefits of encapsulation in the tissue engineering field.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The live cell encapsulation market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European live cell encapsulation market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The live cell encapsulation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The live cell encapsulation market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is expected to dominate the global live cell encapsulation market due to the increasing per capita healthcare expenditure, and the heavy adoption of new technology.
Furthermore, rising expenses in research and development by healthcare bodies and the government is anticipated to drive thegrowth of the market in this region. Apart from this, increasing applications of regenerative medicine in the US is expecting to push the growth of live cell encapsulation market. For instance, According to the National Institutes of Health (NIH), approximately 5,00,000 Americans benefit from a transplant each year.
Europe showed a considerable amount of growth in the global live cell encapsulation market. The market growth in this region is because of the presence of a well-established healthcare system and increase in chronic diseases. For instance, according to cancer research UK, there were approximately 9, 921 cases of cancer diagnosed in 2015. Such high rates of cancer are likely to increase demand for the use of next-generation sequencing as well as increase the market demands for monoclonal bodies and cellular research. These factors are expected to have a positive impact on the live cell encapsulation market.
Asia-Pacific is expected to have a sturdy growth rate during the forecast period owing to the huge patient pool of chronic diseases and government initiatives of healthcare reforms. However, less capital investment is restricting the market growth of this region.
On the other hand, the Middle East & Africa has the least share of the market due to the low disposable income. Moreover, the limited adoption of advanced healthcare facilities and limited access to treatment facilities is also expected to drive the growth of the market in the near future.
Posted by at No comments:
Subscribe to: Posts (Atom)